Showing results (821-830 of 1,033) with videos related to

Sort By:
Pageof 104
The Lancet. Respiratory Medicine|October 20, 2019
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trialYunpeng Yang, Jianya Zhou, Jianying Zhou, et al.
The Lancet. Respiratory Medicine|December 8, 2023
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trialCarlos Ferrando, Albert Carramiñana, Patricia Piñeiro, et al.
The Lancet. Respiratory Medicine|November 5, 2023
Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus studySarah L Gorst, Nina Seylanova, Susanna R Dodd, et al.
The Lancet. Respiratory Medicine|September 12, 2023
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapyKatherine B Hisert, Susan E Birket, John Paul Clancy, et al.
The Lancet. Respiratory Medicine|October 22, 2023
Shaping urban environments to improve respiratory health: recommendations for research, planning, and policyMark Nieuwenhuijsen, Audrey de Nazelle, Judith Garcia-Aymerich, et al.
The Lancet. Respiratory Medicine|September 25, 2023
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study
The Lancet. Respiratory Medicine|July 20, 2023
Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illnessPratik Pandharipande, Shawniqua Williams Roberson, Fiona E Harrison, et al.
The Lancet. Respiratory Medicine|July 15, 2023
Ultra-low tidal volume ventilation for COVID-19-related ARDS in France (VT4COVID): a multicentre, open-label, parallel-group, randomised trialJean-Christophe Richard, Nicolas Terzi, Hodane Yonis, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
The Lancet. Respiratory Medicine|February 11, 2019
Lung transplantation for idiopathic pulmonary fibrosisPeter M George, Caroline M Patterson, Anna K Reed, et al.
Pageof 104